Table 1.
Demographic and clinical characteristics of Faroese individuals infected with Omicron in January 2022 (n = 4506) and control subjects (n = 530).
| Cases |
Controls |
|||||
|---|---|---|---|---|---|---|
| All | Adultsa | Childrenb | All | Adultsa | Childrenb | |
| Total (n) | 4506 | 3373 | 1133 | 530 | 515 | 14 |
|
Age (years), median (5%–95% percentile) |
34.2 (5.1 – 64.0) |
41.0 (18.9 – 66.0) |
9.2 (1.8–15.1) |
54.5 (20.9–74.4) |
54.8 (25.0–74.6) |
8.8 (3.9–14.7) |
| Age groups, n (%) | ||||||
| 0 - 9 | 656 (14.6) | - | 656 (14.6) | 7 (1.3) | - | 7 (1.3) |
| 10 – 15 | 477 (10.6) | - | 477 (10.6) | 7 (1.3) | - | 7 (1.3) |
| 16 – 34 | 1186 (26.3) | 1186 (26.3) | - | 76 (14.3) | 76 (14.3) | - |
| 35 – 49 | 1214 (26.9) | 1214 (26.9) | - | 131 (24.7) | 131 (24.7) | - |
| 50 – 66 | 830 (18.4) | 830 (18.4) | - | 205 (38.7) | 205 (38.7) | - |
| 67+ | 143 (3.2) | 143 (3.2) | - | 104 (19.7) | 104 (19.7) | - |
| Sex, n (%) | ||||||
| Women | 2767 (61.4) | 2175 (64.5) | 592 (52.3) | 244 (46.0) | 240 (46.6) | 4 (28.6) |
| Men | 1739 (38.6) | 1198 (35.5) | 541 (47.8) | 286 (54.0) | 275 (53.4) | 10 (71.4) |
| Ever smoker, n (%)d | ||||||
| Yes | 1678 (32.7) | 1673 (50.3) | 5 (0.44) | 312 (59.3) | 311 (60.9) | 0 (0) |
| No | 2782 (62.4) | 1654 (49.7) | 1128 (99.56) | 214 (40.7) | 200 (39.1) | 14 (100) |
|
Body mass index (kg/m2)e median (5%–95%) |
24.4 (15.2–32.0) |
25.9 (20.3–35.9) |
17.2 (13.5–24.8) |
26.8 (20.3–35.6) |
26.9 (21.1–35.5) |
17.1 (14.2–39.0) |
| Medication, n (%)f | ||||||
| Yes | 1010 (22.7) | 955 (28.6) | 55 (4.9) | 258 (49.1) | 256 (50.1) | 2 (14.3) |
| No | 3443 (77.3) | 2384 (71.4) | 1059 (95.1) | 268 (51.0) | 255 (49.9) | 12 (85.7) |
| Self-reported diseases, n (%)c | ||||||
| Yes | 1336 (29.7) | 1236 (36.6) | 100 (8.8) | 267 (50.4) | 265 (51.5) | 2 (14.3) |
| No | 3170 (70.4) | 2137 (63.4) | 1033 (91.2) | 263 (49.6) | 250 (48.5) | 12 (85.7) |
| Vaccine status,n (%) | ||||||
| None | 1151 (25.5) | 244 (7.2) | 907 (80.1) | 29 (5.5) | 21 (4.1) | 8 (57.1) |
| One | 62 (1.4) | 31 (0.9) | 31 (2.7) | 5 (0.9) | 3 (0.6) | 2 (14.3) |
| Two | 1933 (42.9) | 1740 (51.6) | 193 (17.0) | 113 (21.3) | 108 (21.0) | 4 (28.6) |
| Three | 1360 (30.2) | 1358 (40.3) | 2 (0.2) | 383 (72.3) | 383 (74.4) | 0 (0) |
| COVID previously, n (%)g | ||||||
| Yes | 201 (4.5) | 140 (4.2) | 61 (5.4) | 39 (7.4) | 36 (7.0) | 3 (21.4) |
| No | 4289 (95.5) | 3218 (95.8) | 1071 (94.6) | 491 (92.6) | 479 (93.0) | 11 (78.6) |
| Days since, median (5%–95% percentile) | 111 (35–695) | 135 (65–696) | 97 (67–507) | 123 (80–496) | 114 (79–496) | 129 (89–133) |
|
Duration of acute disease (days)h median (5%–95% percentile) |
3 (0–8) | 3 (0–9) | 2 (0–6) | NA | NA | NA |
| Days from infection to response, median (5%–95% percentile) | 18 (10–30) | 18 (10–29) | 18 (10–32) | NA | NA | NA |
| Days from last vaccination to infection, median (5%–95% percentile) | 109 (9–218) | 111 (9–220) | 85 (9–144) | NA | NA | NA |
a
≥16 years
b
<16 years
c
asthma, heart disease, carnitine transporter deficiency, inflammatory bowel disease, hypertension, hypercholesterolemia, chronic obstructive pulmonary disease, type 2 diabetes
Data missing:
d
n=46 (cases), n=4 (controls)
e
n=127 (cases), n=11 (controls)
f
n=53 (cases), n=19 (controls)
g
n=16 (cases)
h
n=1864 (this question was not in the survey from start)